Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
09 2020
Historique:
received: 05 06 2020
revised: 06 08 2020
accepted: 09 08 2020
entrez: 11 9 2020
pubmed: 12 9 2020
medline: 2 10 2020
Statut: ppublish

Résumé

Early reports suggest the fatality rate from COVID-19 varies greatly across countries, but non-random testing and incomplete vital registration systems render it impossible to directly estimate the infection fatality rate (IFR) in many low- and middle-income countries. To fill this gap, we estimate the adjustments required to extrapolate estimates of the IFR from high-income to lower-income regions. Accounting for differences in the distribution of age, sex and relevant comorbidities yields substantial differences in the predicted IFR across 21 world regions, ranging from 0.11% in Western Sub-Saharan Africa to 1.07% for high-income Asia Pacific. However, these predictions must be treated as lower bounds in low- and middle-income countries as they are grounded in fatality rates from countries with advanced health systems. To adjust for health system capacity, we incorporate regional differences in the relative odds of infection fatality from childhood respiratory syncytial virus. This adjustment greatly diminishes but does not entirely erase the demography-based advantage predicted in the lowest income settings, with regional estimates of the predicted COVID-19 IFR ranging from 0.37% in Western Sub-Saharan Africa to 1.45% for Eastern Europe.

Identifiants

pubmed: 32912856
pii: bmjgh-2020-003094
doi: 10.1136/bmjgh-2020-003094
pmc: PMC7482102
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Lancet Glob Health. 2020 Apr;8(4):e497-e510
pubmed: 32087815
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9696-9698
pubmed: 32300018
Lancet. 2010 May 1;375(9725):1500-2
pubmed: 20399494
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234121
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
BMJ Glob Health. 2020 May;5(5):
pubmed: 32451366
Lancet. 2020 May 30;395(10238):1715-1725
pubmed: 32405103
Lancet Infect Dis. 2020 Jun;20(6):630-631
pubmed: 32240633
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664

Auteurs

Selene Ghisolfi (S)

Institute for International Economic Studies, Stockholm University, Stockholm, Sweden.
LEAP, Bocconi University, Milan, Italy.

Ingvild Almås (I)

Institute for International Economic Studies, Stockholm University, Stockholm, Sweden.

Justin C Sandefur (JC)

Center for Global Development, Washington, DC, USA.

Tillman von Carnap (T)

Institute for International Economic Studies, Stockholm University, Stockholm, Sweden.

Jesse Heitner (J)

Aceso Global, Washington, DC, USA.

Tessa Bold (T)

Institute for International Economic Studies, Stockholm University, Stockholm, Sweden tessa.bold@iies.su.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH